- Home
- HNRG vs TECX Comparison
HNRG vs TECX Comparison
Compare HNRG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- TECX
- Stock Information
- Founded
- HNRG 1949
- TECX 2019
- Country
- HNRG United States
- TECX United States
- Employees
- HNRG N/A
- TECX N/A
- Industry
- HNRG Coal Mining
- TECX
- Sector
- HNRG Energy
- TECX
- Exchange
- HNRG Nasdaq
- TECX Nasdaq
- Market Cap
- HNRG 413.8M
- TECX 334.4M
- IPO Year
- HNRG N/A
- TECX 2018
- Fundamental
- Price
- HNRG $15.31
- TECX $19.76
- Analyst Decision
- HNRG Strong Buy
- TECX Buy
- Analyst Count
- HNRG 2
- TECX 6
- Target Price
- HNRG $16.00
- TECX $72.40
- AVG Volume (30 Days)
- HNRG 700.7K
- TECX 203.0K
- Earning Date
- HNRG 05-12-2025
- TECX 05-08-2025
- Dividend Yield
- HNRG N/A
- TECX N/A
- EPS Growth
- HNRG N/A
- TECX N/A
- EPS
- HNRG N/A
- TECX N/A
- Revenue
- HNRG $404,394,000.00
- TECX N/A
- Revenue This Year
- HNRG N/A
- TECX N/A
- Revenue Next Year
- HNRG $24.45
- TECX N/A
- P/E Ratio
- HNRG N/A
- TECX N/A
- Revenue Growth
- HNRG N/A
- TECX N/A
- 52 Week Low
- HNRG $4.86
- TECX $1.40
- 52 Week High
- HNRG $15.22
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- HNRG 64.72
- TECX 49.14
- Support Level
- HNRG $14.11
- TECX $17.56
- Resistance Level
- HNRG $15.65
- TECX $21.99
- Average True Range (ATR)
- HNRG 0.62
- TECX 1.96
- MACD
- HNRG -0.01
- TECX 0.21
- Stochastic Oscillator
- HNRG 83.41
- TECX 46.15
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.